Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 1.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,563 shares of the medical equipment provider’s stock after selling 1,087 shares during the quarter. Trillium Asset Management LLC’s holdings in Hologic were worth $7,177,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. State Street Corp increased its stake in Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after purchasing an additional 81,057 shares during the last quarter. FMR LLC increased its stake in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. increased its stake in Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after purchasing an additional 24,358 shares during the last quarter. Boston Partners increased its stake in Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after purchasing an additional 1,602,463 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after purchasing an additional 18,774 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Down 0.8 %

Shares of HOLX opened at $61.47 on Thursday. The company has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a one year low of $60.34 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a 50-day moving average price of $66.50 and a 200 day moving average price of $74.28.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HOLX shares. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. Raymond James restated an “outperform” rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.